Sponsored By

Family Behind Oxycontin Faces Lawsuit over Opioid AbuseFamily Behind Oxycontin Faces Lawsuit over Opioid Abuse

The Sackler family found success developing Oxycontin, but at what cost?

Bryan D. Kirk, Managing Director and Trust Counsel

July 10, 2018

4 Min Read
Oxycontin pills
Copyright Darren McCollester, Getty Images

Every professional involved in trusts and estates has the stories:

  • The siblings that inherit the family ranch only to discover an old landfill under the stables when they prepare to sell.

  • The prized collection of historic photographs and memorabilia the family spent thousands to preserve, store and ship around the country only to realize no one wanted them (including themselves).

  • The apartment building a family decides is worth trying to fix up only to have tar blow into the HVAC system when their contractors are working on the roof.

Of course, there are also stories that turn positive. But more numerous are the ones that turn the old adage on its head and make you think the first place to look a gift horse is in its mouth.

Chances are there’s at least one member of the Sackler family who feels that way today. 

Who Are the Sacklers?

As profiled in the New Yorker last year, the Sacklers are the family behind Purdue Pharma, the pharmaceutical company that developed the drug that’s now at the center of the country’s opioid crisis: Oxycontin. The company was built by the Sackler brothers—Arthur, Mortimer and Raymond—all of whom were physicians. Arthur died in 1987, before the advent of Oxycontin, at which point Arthur’s descendants were bought out of the company by Mortimer and Raymond. Mortimer died in 2010, and Raymond died in 2017.

The current directors of Purdue Pharma include three of Mortimer’s children, Ilene Sackler Lefcourt, Kathe and Mortimer Sackler; Raymond’s two sons, Jonathan and Richard Sackler; and Raymond’s grandson, David Sackler. The family has an estimated net worth of $13 billion spread among approximately 20 members. As described in the New Yorker article, the Mortimer brothers “donated lavishly during their lifetimes to an astounding range of institutions, many of which bear the family name: the Sackler Gallery, in Washington; the Sackler Museum, at Harvard; the Sackler Center for Arts Education, at the Guggenheim; the Sackler Wing, at the Louvre; and Sackler institutes and facilities at Columbia, Oxford, and a dozen other universities.”

Yet the role of Oxycontin in the opioid crisis and the role of Purdue in developing and marketing the drug has brought a harsh spotlight on the family. The company has been named in hundreds of lawsuits alleging liability for the company’s role in the spread of Oxycontin abuse, opioid-related deaths and other public costs. In March, protesters converged on the Sackler Wing of the Metropolitan Museum of Art, threw pill bottles, called for cultural institutions to refuse donations from the Sackler family and demanded that Purdue fund treatment for addicts.

Massachusetts Lawsuit

Now, family members have personally been named as defendants in the latest lawsuit filed by Massachusetts Attorney General Maura Healey. The lawsuit alleges causes of action for (1) unfair and deceptive acts and practices, (2) public nuisance and (3) negligence, and names each of the six family board members as well as the company’s CEOs as defendants. It claims they had “oversight and control over the unlawful sales and marketing” of Oxycontin and “are personally liable for the misconduct because: (a) they participated in the misconduct; and/or (b) they knew about the misconduct and failed to stop it; and/or (c) they should have known about the misconduct and they failed to stop it.” 

Family Concepts of Success

Putting aside the ultimate outcome of the Massachusetts lawsuit (and others), as well as the  underlying culpability of the individual family members, the existence of the lawsuit highlights a key aspect of family business planning that can be overlooked.

From a family business planning perspective, the Sackler family could be viewed as a success.  Arthur’s descendants were able to be bought out. Members of both the second and third generations are involved in management. The company remains privately held and has generated substantial profits.

The issue is the cost at which the profits were won. From a planning perspective, the questions worth asking are: Did each family member consciously make that bargain? Did they ever have the chance? Did they have the necessary information? Did they have the necessary advice? To what extent would they have needed to sacrifice? To what extent did they understand the potential costs?

These questions don’t diminish the responsibility of each family member. Rather, they’re intended to highlight the need for professionals to press against a family’s concepts of success—especially when seemingly valued assets can easily become liabilities. 

About the Author

Bryan D. Kirk

Managing Director and Trust Counsel, Fiduciary Trust Company International

Bryan D. Kirk, Managing Director and Trust Counsel, is a senior trusts and estates advisor for Fiduciary Trust Company International, where he provides guidance on all aspects of estate planning and trust and estate administration. Mr. Kirk has broad experience in multi-generational asset management and transfer planning, including estate, gift, generation-skipping transfer and income tax planning, charitable giving, philanthropy, real property matters and complex assets, such as private equity and debt. He also serves as Chief Fiduciary Officer of Fiduciary Trust Company International of California. Before joining Fiduciary Trust Company International, he was a partner with Botto Law Group LLP in San Francisco. Mr. Kirk earned his law degree from University of California, Berkeley, and graduated cum laude from Claremont McKenna College with a Bachelor of Arts degree in literature and government.

You May Also Like